United States Financial Markets News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Search entities
Discover all 32,649 supported financial entities for United States financial markets here.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 1246,
"returned": 10,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "388ef67e-212e-45fe-8106-40cf52c4c04b",
"title": "Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | IMTX Stock News",
"description": "Immatics' IMA203 PRAME cell therapy shows a 56% confirmed objective response rate in metastatic melanoma patients. The therapy demonstrates strong durab",
"keywords": "GuruFocus, Article, News, GuruFocus News, IMTX",
"snippet": "Immatics' IMA203 PRAME cell therapy shows a 56% confirmed objective response rate in metastatic melanoma patients.\n\nThe therapy demonstrates strong durability w...",
"url": "https://www.gurufocus.com/news/2899922/immatics-ima203-prame-cell-therapy-data-presented-at-2025-asco-annual-meeting-continues-to-show-strong-antitumor-activity-and-durability-in-patients-with-metastatic-melanoma-imtx-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BVAE.png?20",
"language": "en",
"published_at": "2025-05-31T13:16:14.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "IMTX",
"name": "Immatics N.V.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 48.957344,
"sentiment_score": 0.3071,
"highlights": [
{
"highlight": "<em>Immatics</em>' IMA203 PRAME cell the[+321 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Immatics</em> <em>N.V</em>. (IMTX, F[+210 characters]",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "Encouraged by these results and the high[+281 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "The SUPRAME trial's primary endpoint is [+273 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Immatics</em> IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma | IMTX Stock News",
"sentiment": 0.5106,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "1ce66c47-defa-42e5-be95-5e8dcb2307e2",
"title": "Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma",
"description": "**media[642064]**",
"keywords": "Immatics, IMA203, PRAME, Cell, Therapy, Data, Presented, at, 2025, ASCO, Annual, Meeting, Continues, to, Show, Strong, Anti-tumor, Activity, and, Durability, in, Patients, with, Metastatic, Melanoma",
"snippet": "Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability an...",
"url": "https://www.manilatimes.net/2025/05/31/tmt-newswire/globenewswire/immatics-ima203-prame-cell-therapy-data-presented-at-2025-asco-annual-meeting-continues-to-show-strong-anti-tumor-activity-and-durability-in-patients-with-metastatic-melanoma/2124533",
"image_url": "https://www.manilatimes.net/manilatimes/uploads/images/2025/05/31/642064.png",
"language": "en",
"published_at": "2025-05-31T12:09:34.000000Z",
"source": "manilatimes.net",
"relevance_score": null,
"entities": [
{
"symbol": "IMTX",
"name": "Immatics N.V.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 49.362354,
"sentiment_score": 0.147191,
"highlights": [
{
"highlight": "' global leadership in precision targeti[+123 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "(<em>NASDAQ</em>: <em>IMTX</em>, \"<em>Im[+348 characters]",
"sentiment": -0.4019,
"highlighted_in": "main_text"
},
{
"highlight": "These individuals are in urgent need of [+136 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
},
{
"highlight": "Trial-in-Progress Poster Summary - IMA20[+231 characters]",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Immatics</em> aims to submit a Biolo[+294 characters]",
"sentiment": 0.4767,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>Immatics</em> PRAME franchise cu[+282 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Immatics</em>\n\n<em>Immatics</e[+206 characters]",
"sentiment": -0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Immatics</em> intends to use its web[+265 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "These forward-looking statements are bas[+255 characters]",
"sentiment": -0.8481,
"highlighted_in": "main_text"
},
{
"highlight": "For more information, please contact:\n\nM[+85 characters]",
"sentiment": 0.3774,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Immatics</em> IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma",
"sentiment": 0.5106,
"highlighted_in": "title"
}
]
},
{
"symbol": "FRGAP",
"name": "Franchise Group, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 7.529414,
"sentiment_score": -0.0286,
"highlights": [
{
"highlight": "We view our progress in melanoma as a cr[+293 characters]",
"sentiment": -0.3818,
"highlighted_in": "main_text"
},
{
"highlight": "Immatics is the global leader in precisi[+115 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "The Immatics PRAME <em>franchise</em> cu[+282 characters]",
"sentiment": 0.296,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "2019a865-9d25-4977-ac19-ace4217cad96",
"title": "Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer | GILD Stock News",
"description": "Gilead Sciences (GILD) unveils breakthrough results from its Phase 3 trial for metastatic triple-negative breast cancer (TNBC). The combination of Trode",
"keywords": "GuruFocus, Article, News, GuruFocus News, GILD",
"snippet": "Gilead Sciences (GILD, Financial) unveils breakthrough results from its Phase 3 trial for metastatic triple-negative breast cancer (TNBC).\n\nThe combination of T...",
"url": "https://www.gurufocus.com/news/2899921/trodelvy-plus-keytruda-reduces-risk-of-disease-progression-or-death-by-35-versus-keytruda-and-chemotherapy-in-firstline-pdl1-metastatic-triplenegative-breast-cancer-gild-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000007VR.png?20",
"language": "en",
"published_at": "2025-05-31T13:16:09.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GILD",
"name": "Gilead Sciences, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 43.56643,
"sentiment_score": 0.1901,
"highlights": [
{
"highlight": "<em>Gilead</em> <em>Sciences</em> (GILD,[+316 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Gilead</em> <em>Sciences</em>, <em>I[+149 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "8f176243-d84c-4702-8520-4a55ecf7e708",
"title": "Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer | ARVN Stock News",
"description": "Vepdegestrant shows a significant 2.9-month improvement in median progression-free survival in ESR1-mutant breast cancer patients. Arvinas (ARVN) and Pf",
"keywords": "GuruFocus, Article, News, GuruFocus News, ARVN",
"snippet": "Vepdegestrant shows a significant 2.9-month improvement in median progression-free survival in ESR1-mutant breast cancer patients.\n\nArvinas (ARVN, Financial) an...",
"url": "https://www.gurufocus.com/news/2899916/arvinas-and-pfizers-vepdegestrant-significantly-improves-progressionfree-survival-for-patients-with-esr1mutant-erher2-advanced-breast-cancer-arvn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BIBF.png?20",
"language": "en",
"published_at": "2025-05-31T13:15:39.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ARVN",
"name": "Arvinas, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 46.04847,
"sentiment_score": -0.21315,
"highlights": [
{
"highlight": "<em>Arvinas</em> (ARVN, Financial) and P[+254 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Arvinas</em> and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer | ARVN Stock News",
"sentiment": -0.1531,
"highlighted_in": "title"
}
]
},
{
"symbol": "PFE",
"name": "Pfizer Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 22.52349,
"sentiment_score": -0.2732,
"highlights": [
{
"highlight": "Arvinas (ARVN, Financial) and <em>Pfizer[+254 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "PFE-WI",
"name": "Pfizer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 22.52349,
"sentiment_score": -0.2732,
"highlights": [
{
"highlight": "Arvinas (ARVN, Financial) and <em>Pfizer[+254 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "7a204204-ec07-467a-84b4-9dde533d59d9",
"title": "Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing | REGN Stock News",
"description": "Libtayo® (cemiplimab) Phase 3 trial shows 68% reduction in disease recurrence or death risk for high-risk CSCC after surgery. Trial reveals 87% disease",
"keywords": "GuruFocus, Article, News, GuruFocus News, REGN",
"snippet": "Libtayo® (cemiplimab) Phase 3 trial shows 68% reduction in disease recurrence or death risk for high-risk CSCC after surgery.\n\nTrial reveals 87% disease-free s...",
"url": "https://www.gurufocus.com/news/2899915/libtayo-cemiplimab-phase-3-data-in-the-adjuvant-treatment-of-postsurgical-highrisk-cutaneous-squamous-cell-carcinoma-cscc-have-potential-to-be-practicechanging-regn-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C000008R4.png?20",
"language": "en",
"published_at": "2025-05-31T13:15:27.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "REGN",
"name": "Regeneron Pharmaceuticals, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.920944,
"sentiment_score": 0.2023,
"highlights": [
{
"highlight": "<em>Regeneron</em> <em>Pharmaceuticals</[+231 characters]",
"sentiment": 0.2023,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "e7ca6554-66d9-4e57-aea0-9f4f08113275",
"title": "In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to Enable Ti",
"description": "Guardant Health (GH) reveals findings from the largest study on molecular residual disease (MRD) in colon cancer. The Guardant Revealâ„¢ test can predic",
"keywords": "GuruFocus, Article, News, GuruFocus News, GH",
"snippet": "Guardant Health (GH, Financial) reveals findings from the largest study on molecular residual disease (MRD) in colon cancer.\n\nThe Guardant Reveal™ test can pr...",
"url": "https://www.gurufocus.com/news/2899913/in-largest-molecular-residual-disease-mrd-study-in-colon-cancer-guardant-reveal-testing-prior-to-chemotherapy-provides-robust-stratification-for-risk-of-disease-recurrence-and-survival-to-enable-ti",
"image_url": "https://static.gurufocus.com/logos/0C0000BIF0.png?20",
"language": "en",
"published_at": "2025-05-31T13:15:17.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GH",
"name": "Guardant Health, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 45.36103,
"sentiment_score": -0.313233,
"highlights": [
{
"highlight": "<em>Guardant</em> <em>Health</em> (GH, F[+319 characters]",
"sentiment": -0.6597,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Guardant</em> <em>Health</em>, <em>I[+202 characters]",
"sentiment": -0.7906,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Guardant</em> <em>Health</em>:[+324 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "7b05aa10-6f6b-4c91-9263-97ffa4f9ad1c",
"title": "Strauss Group Ltd (XTAE:STRS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges",
"description": "Revenue Growth: 15.5% increase year-over-year; 23% growth excluding divested units Sabra & Obela and Serbia.EBIT: ILS181 million, an 11.2% decline year-over-ye",
"keywords": "GuruFocus, Article, News, GuruFocus News, XTAE:STRS",
"snippet": "Release Date: May 28, 2025\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nPositive Points\n\nStrauss Group...",
"url": "https://www.gurufocus.com/news/2899911/strauss-group-ltd-xtaestrs-q1-2025-earnings-call-highlights-navigating-growth-amidst-challenges",
"image_url": "https://static.gurufocus.com/logos/0C00008JGD.png?5",
"language": "en",
"published_at": "2025-05-31T13:00:31.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "SGLJF",
"name": "Strauss Group Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 134.79128,
"sentiment_score": 0.512633,
"highlights": [
{
"highlight": "Positive Points\n\n<em>Strauss</em> <em>Gr[+304 characters]",
"sentiment": 0.9196,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Strauss</em> <em>Group</em> <em>Ltd<[+295 characters]",
"sentiment": 0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Strauss</em> <em>Group</em> <em>Ltd</em> (XTAE:STRS) Q1 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges",
"sentiment": 0.4404,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "1addc56d-43ea-4f38-a29c-a3371c9cfab8",
"title": "Auto Trader Group PLC (ATDRF) Full Year 2025 Earnings Call Highlights: Strong Revenue and Profit Growth Amid Market Challenges",
"description": "Group Revenue Growth: 5% increase.Operating Profit Growth: 8% increase.Basic EPS Growth: 12% increase.Core Auto Trader Revenue Growth: 7% increase.Retailer Rev",
"keywords": "GuruFocus, Article, News, GuruFocus News, ATDRF",
"snippet": "Release Date: May 29, 2025\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nPositive Points\n\nAuto Trader G...",
"url": "https://www.gurufocus.com/news/2899895/auto-trader-group-plc-atdrf-full-year-2025-earnings-call-highlights-strong-revenue-and-profit-growth-amid-market-challenges",
"image_url": "https://static.gurufocus.com/logos/0C0000AV8E.png?5",
"language": "en",
"published_at": "2025-05-31T11:00:32.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "ATDRY",
"name": "Auto Trader Group plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 107.037964,
"sentiment_score": 0.546925,
"highlights": [
{
"highlight": "Positive Points\n\n<em>Auto</em> <em>Trade[+277 characters]",
"sentiment": 0.9423,
"highlighted_in": "main_text"
},
{
"highlight": "Q & A Highlights\n\nQ: With the April '26 [+282 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Nathan Coe, CEO, added that Autorama's f[+258 characters]",
"sentiment": 0.128,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Auto</em> <em>Trader</em> <em>Group</em> <em>PLC</em> (ATDRF) Full Year 2025 Earnings Call Highlights: Strong Revenue and Profit Growth Amid Market Challenges",
"sentiment": 0.8442,
"highlighted_in": "title"
}
]
},
{
"symbol": "ATDRF",
"name": "Auto Trader Group plc",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 147.61148,
"sentiment_score": 0.546925,
"highlights": [
{
"highlight": "Positive Points\n\n<em>Auto</em> <em>Trade[+286 characters]",
"sentiment": 0.9423,
"highlighted_in": "main_text"
},
{
"highlight": "Q & A Highlights\n\nQ: With the April '26 [+282 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Nathan Coe, CEO, added that Autorama's f[+258 characters]",
"sentiment": 0.128,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Auto</em> <em>Trader</em> <em>Group</em> <em>PLC</em> (<em>ATDRF</em>) Full Year 2025 Earnings Call Highlights: Strong Revenue and Profit Growth Amid Market Challenges",
"sentiment": 0.8442,
"highlighted_in": "title"
}
]
},
{
"symbol": "AUTO.L",
"name": "Auto Trader Group plc",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "Communication Services",
"match_score": 107.0401,
"sentiment_score": 0.546925,
"highlights": [
{
"highlight": "Positive Points\n\n<em>Auto</em> <em>Trade[+277 characters]",
"sentiment": 0.9423,
"highlighted_in": "main_text"
},
{
"highlight": "Q & A Highlights\n\nQ: With the April '26 [+282 characters]",
"sentiment": 0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "Nathan Coe, CEO, added that Autorama's f[+258 characters]",
"sentiment": 0.128,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Auto</em> <em>Trader</em> <em>Group</em> <em>PLC</em> (ATDRF) Full Year 2025 Earnings Call Highlights: Strong Revenue and Profit Growth Amid Market Challenges",
"sentiment": 0.8442,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "930bee6e-6ae3-4da2-9dd6-266503294289",
"title": "Shoe Carnival Inc (SCVL) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives",
"description": "Net Sales: $277.7 million, a decline of 7.5% compared to last year.Net Income: $9.3 million or $0.34 per diluted share, down from $17.3 million or $0.63 per di",
"keywords": "GuruFocus, Article, News, GuruFocus News, SCVL",
"snippet": "Release Date: May 30, 2025\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nPositive Points\n\nShoe Carnival...",
"url": "https://www.gurufocus.com/news/2899889/shoe-carnival-inc-scvl-q1-2025-earnings-call-highlights-navigating-challenges-with-strategic-initiatives",
"image_url": "https://static.gurufocus.com/logos/0C0000090L.png?5",
"language": "en",
"published_at": "2025-05-31T07:01:20.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "SCVL",
"name": "Shoe Carnival, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 125.16372,
"sentiment_score": 0.397488,
"highlights": [
{
"highlight": "Positive Points\n\n<em>Shoe</em> <em>Carni[+281 characters]",
"sentiment": 0.9201,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Shoe</em> <em>Carnival</em> <em>Inc<[+265 characters]",
"sentiment": 0.7351,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Shoe</em> <em>Carnival</em> <em>Inc<[+336 characters]",
"sentiment": -0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "The <em>Shoe</em> <em>Carnival</em> bann[+257 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Shoe</em> <em>Carnival</em> <em>Inc<[+294 characters]",
"sentiment": 0.1531,
"highlighted_in": "main_text"
},
{
"highlight": "The competitive set for Shoe Station is [+308 characters]",
"sentiment": 0.4706,
"highlighted_in": "main_text"
},
{
"highlight": "A: Mark Worden indicated that the guidan[+266 characters]",
"sentiment": 0.5106,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Shoe</em> <em>Carnival</em> <em>Inc</em> (SCVL) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives",
"sentiment": 0.0772,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "81bff1d4-609a-432d-b463-7770f86657c3",
"title": "Laurentian Bank of Canada (LRCDF) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth",
"description": "Total Revenue: $242.5 million, down 4% year-over-year and 3% quarter-to-quarter.Net Income (Reported): $32.3 million.Diluted EPS (Reported): $0.69.Net Income (",
"keywords": "GuruFocus, Article, News, GuruFocus News, LRCDF",
"snippet": "Release Date: May 30, 2025\n\nFor the complete transcript of the earnings call, please refer to the full earnings call transcript.\n\nPositive Points\n\nLaurentian Ba...",
"url": "https://www.gurufocus.com/news/2899885/laurentian-bank-of-canada-lrcdf-q2-2025-earnings-call-highlights-navigating-challenges-with-strategic-growth",
"image_url": "https://static.gurufocus.com/logos/0C00000I4J.png?5",
"language": "en",
"published_at": "2025-05-31T07:01:05.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "LRCDF",
"name": "Laurentian Bank of Canada",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 191.74954,
"sentiment_score": 0.761967,
"highlights": [
{
"highlight": "Positive Points\n\n<em>Laurentian</em> <em[+211 characters]",
"sentiment": 0.9118,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Laurentian</em> <em>Bank</em> <em>of[+290 characters]",
"sentiment": 0.9337,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Laurentian</em> <em>Bank</em> <em>of</em> <em>Canada</em> (<em>LRCDF</em>) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth",
"sentiment": 0.4404,
"highlighted_in": "title"
}
]
},
{
"symbol": "LB-PJ.TO",
"name": "Laurentian Bank of Canada",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Financial Services",
"match_score": 151.19289,
"sentiment_score": 0.761967,
"highlights": [
{
"highlight": "Positive Points\n\n<em>Laurentian</em> <em[+202 characters]",
"sentiment": 0.9118,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Laurentian</em> <em>Bank</em> <em>of[+281 characters]",
"sentiment": 0.9337,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Laurentian</em> <em>Bank</em> <em>of</em> <em>Canada</em> (LRCDF) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth",
"sentiment": 0.4404,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "3e08bb10-523a-4374-9902-d97c6e729ac7",
"title": "RDDT INVESTIGATION NOTICE: Reddit, Inc. is being Investigated for Securities Fraud -- Contact BFA Law if You Suffered Losses (NYSE:RDDT)",
"description": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Reddit, Inc. (: RDDT) for po",
"keywords": "GuruFocus, Article, News, Marketwired, RDDT",
"snippet": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Reddit, Inc. (: RDDT) for pote...",
"url": "https://www.gurufocus.com/news/2899906/rddt-investigation-notice-reddit-inc-is-being-investigated-for-securities-fraud-contact-bfa-law-if-you-suffered-losses-nyserddt",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T13:00:03.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TSLA",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 15.071484,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
}
],
"similar": [
{
"uuid": "3e08bb10-523a-4374-9902-d97c6e729ac7",
"title": "RDDT INVESTIGATION NOTICE: Reddit, Inc. is being Investigated for Securities Fraud -- Contact BFA Law if You Suffered Losses (NYSE:RDDT)",
"description": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Reddit, Inc. (: RDDT) for po",
"keywords": "GuruFocus, Article, News, Marketwired, RDDT",
"snippet": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Reddit, Inc. (: RDDT) for pote...",
"url": "https://www.gurufocus.com/news/2899906/rddt-investigation-notice-reddit-inc-is-being-investigated-for-securities-fraud-contact-bfa-law-if-you-suffered-losses-nyserddt",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T13:00:03.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TL0.DE",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 15.071484,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TSLA",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 15.071484,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TSLA.MX",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 15.071499,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "fd99a723-eab5-48ed-a5b6-74f2d1473242",
"title": "CIVI CLASS NOTICE: Civitas Resources, Inc. Investors may have been Affected by Fraud -- Contact BFA Law before July 1 Court Deadline (NYSE:CIVI)",
"description": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Civitas Reso",
"keywords": "GuruFocus, Article, News, Marketwired, CIVI",
"snippet": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Civitas Resour...",
"url": "https://www.gurufocus.com/news/2899905/civi-class-notice-civitas-resources-inc-investors-may-have-been-affected-by-fraud-contact-bfa-law-before-july-1-court-deadline-nysecivi",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T13:00:03.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TL0.DE",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 13.570639,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TSLA",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 13.570639,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TSLA.MX",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 13.570648,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "4d0c4ea4-b34a-4cc1-bd34-30529e746cc0",
"title": "CODI CLASS NOTICE: Compass Diversified Holdings Investors may have been Affected by Fraud -- Contact BFA Law before July 8 Court Deadline (NYSE:CODI)",
"description": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Compass Dive",
"keywords": "GuruFocus, Article, News, Marketwired, CODI",
"snippet": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Compass Divers...",
"url": "https://www.gurufocus.com/news/2899904/codi-class-notice-compass-diversified-holdings-investors-may-have-been-affected-by-fraud-contact-bfa-law-before-july-8-court-deadline-nysecodi",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T13:00:03.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "TL0.DE",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 13.570639,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TSLA",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 13.570639,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "CODI",
"name": "Compass Diversified",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Industrials",
"match_score": 119.55527,
"sentiment_score": -0.061567,
"highlights": [
{
"highlight": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) [+311 characters]",
"sentiment": 0.5267,
"highlighted_in": "main_text"
},
{
"highlight": "If you invested in Compass you are encou[+229 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "Click here if you suffered losses: https[+293 characters]",
"sentiment": -0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "Submit your information by visiting:\n\nht[+327 characters]",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "https://www.bfalaw.com/cases-investigati[+120 characters]",
"sentiment": -0.0754,
"highlighted_in": "main_text"
},
{
"highlight": "CODI CLASS NOTICE: <em>Compass</em> <em>Diversified</em> Holdings Investors may have been Affected by Fraud -- Contact BFA Law before July 8 Court Deadline (<em>NYSE:CODI</em>)",
"sentiment": -0.6597,
"highlighted_in": "title"
}
]
},
{
"symbol": "TSLA.MX",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 13.570648,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "47e0f5bd-4fca-4852-8227-376de859fffc",
"title": "BBAI CLASS NOTICE: BigBear.ai Holdings, Inc. Investors may have been Affected by Fraud -- Contact BFA Law before June 10 Court Deadline (NYSE:BBAI)",
"description": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BigBear.ai H",
"keywords": "GuruFocus, Article, News, Marketwired, BBAI",
"snippet": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BigBear.ai Hol...",
"url": "https://www.gurufocus.com/news/2899902/bbai-class-notice-bigbearai-holdings-inc-investors-may-have-been-affected-by-fraud-contact-bfa-law-before-june-10-court-deadline-nysebbai",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T13:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "GIGGU",
"name": "GigCapital4, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 32.20625,
"sentiment_score": 0.0258,
"highlights": [
{
"highlight": "BigBear.ai went public via a special pur[+319 characters]",
"sentiment": 0.0258,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GIG",
"name": "GigCapital4, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Financial Services",
"match_score": 32.20625,
"sentiment_score": 0.0258,
"highlights": [
{
"highlight": "BigBear.ai went public via a special pur[+319 characters]",
"sentiment": 0.0258,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "GIGGW",
"name": "GigCapital4, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "N/A",
"match_score": 32.20625,
"sentiment_score": 0.0258,
"highlights": [
{
"highlight": "BigBear.ai went public via a special pur[+319 characters]",
"sentiment": 0.0258,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TL0.DE",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 12.934196,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TSLA",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 12.934196,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TSCC",
"name": "Technology Solutions Company",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 16.614788,
"sentiment_score": 0.6908,
"highlights": [
{
"highlight": "BigBear.ai is an AI-driven <em>technolog[+248 characters]",
"sentiment": 0.6908,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TSLA.MX",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 12.934204,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
}
]
},
{
"uuid": "a0b102bf-473d-4926-9eb0-b12daba42826",
"title": "URGN CLASS ACTION NOTICE: UroGen Pharma Ltd. has been Sued for Securities Fraud after Stock Plummets 45% -- Contact BFA Law if You Suffered Losses (NASDAQ:URGN)",
"description": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharm",
"keywords": "GuruFocus, Article, News, Marketwired, URGN",
"snippet": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against UroGen Pharma ...",
"url": "https://www.gurufocus.com/news/2899903/urgn-class-action-notice-urogen-pharma-ltd-has-been-sued-for-securities-fraud-after-stock-plummets-45-contact-bfa-law-if-you-suffered-losses-nasdaqurgn",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T13:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "URGN",
"name": "UroGen Pharma Ltd.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 146.4266,
"sentiment_score": -0.264014,
"highlights": [
{
"highlight": "NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) [+265 characters]",
"sentiment": 0.0516,
"highlighted_in": "main_text"
},
{
"highlight": "If you invested in UroGen you are encour[+248 characters]",
"sentiment": 0.3612,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UroGen</em> <em>Pharma</em> <em>Ltd<[+296 characters]",
"sentiment": -0.743,
"highlighted_in": "main_text"
},
{
"highlight": "Click here if you suffered losses: https[+312 characters]",
"sentiment": -0.6249,
"highlighted_in": "main_text"
},
{
"highlight": "Submit your information by visiting:\n\nht[+202 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "https://www.bfalaw.com/cases-investigati[+139 characters]",
"sentiment": -0.0754,
"highlighted_in": "main_text"
},
{
"highlight": "URGN CLASS ACTION NOTICE: <em>UroGen</em> <em>Pharma</em> <em>Ltd</em>. has been Sued for Securities Fraud after Stock Plummets 45% -- Contact BFA Law if You Suffered Losses (<em>NASDAQ:URGN</em>)",
"sentiment": -0.8176,
"highlighted_in": "title"
}
]
},
{
"symbol": "TL0.DE",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "de",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 12.934196,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TSLA",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 12.934196,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
},
{
"symbol": "TSLA.MX",
"name": "Tesla, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Consumer Cyclical",
"match_score": 12.934204,
"sentiment_score": 0.8555,
"highlights": [
{
"highlight": "Among its recent notable successes, BFA [+242 characters]",
"sentiment": 0.8555,
"highlighted_in": "main_text"
}
]
}
]
}
]
},
{
"uuid": "27f70a82-88df-4bad-8581-c78a72ff63c0",
"title": "Kuaishou Technology Stock: High-Teens EPS Growth Is Plausible (OTCMKTS:KUASF)",
"description": "Solid earnings growth, reaccelerating advertising, and robust e-commerce drive Kuaishou Technology's future. Read more on KUASF stock here.",
"keywords": "",
"snippet": "My previous investment thought on Kuaishou Technology ( OTCPK:KUASF ) was a buy rating because the valuation was still cheap and I expected growth to accelerate...",
"url": "https://seekingalpha.com/article/4791428-kuaishou-technology-high-teens-eps-growth-is-plausible",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177041055/image_2177041055.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2025-05-31T12:55:54.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "KUASF",
"name": "Kuaishou Technology",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Communication Services",
"match_score": 124.27244,
"sentiment_score": 0.50935,
"highlights": [
{
"highlight": "My previous investment thought on <em>Ku[+276 characters]",
"sentiment": 0.6369,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Kuaishou</em> <em>Technology</em> Stock: High-Teens EPS Growth Is Plausible (OTCMKTS:KUASF)",
"sentiment": 0.3818,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "2a6c3723-4e55-4336-a67f-447af066f6b9",
"title": "Super Micro Computer Stock: Overhyped AI Story With Underwhelming Delivery (NASDAQ:SMCI)",
"description": "Learn why Super Micro Computer's (SMCI) weak Q3 results, poor guidance, and execution risks justify a bearish outlook despite AI infrastructure market growth.",
"keywords": "",
"snippet": "Experience as an investment analyst for a major BB-Bank, as well as private equity consultant for MBB. Currently working towards the CFA charter, having complet...",
"url": "https://seekingalpha.com/article/4791422-super-micro-computer-overhyped-ai-story-with-underwhelming-delivery",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/885294108/image_885294108.jpg?io=getty-c-w1536",
"language": "en",
"published_at": "2025-05-31T12:19:54.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "SMCI",
"name": "Super Micro Computer, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 109.6831,
"sentiment_score": 0,
"highlights": [
{
"highlight": "<em>Super</em> <em>Micro</em> <em>Computer</em> Stock: Overhyped AI Story With Underwhelming Delivery (<em>NASDAQ:SMCI</em>)",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "837508af-d91b-450b-84f4-81db142786f7",
"title": "Moderna (MRNA) Gains FDA Approval for New COVID-19 Vaccine",
"description": "Moderna secures FDA approval for the innovative mNEXSPIKE COVID-19 vaccine. Analysts predict a 76.39% upside potential for Moderna's stock. GuruFocus",
"keywords": "GuruFocus, Article, News, GuruFocus News, MRNA",
"snippet": "Moderna secures FDA approval for the innovative mNEXSPIKE COVID-19 vaccine.\n\nAnalysts predict a 76.39% upside potential for Moderna's stock.\n\nGuruFocus projects...",
"url": "https://www.gurufocus.com/news/2899900/moderna-mrna-gains-fda-approval-for-new-covid19-vaccine",
"image_url": "https://static.gurufocus.com/logos/0C0000BJB3.png?20",
"language": "en",
"published_at": "2025-05-31T12:55:17.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 45.513313,
"sentiment_score": 0.358986,
"highlights": [
{
"highlight": "<em>Moderna</em> secures FDA approval fo[+204 characters]",
"sentiment": 0.743,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> (MRNA, Financial) has r[+250 characters]",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "Wall Street Analysts Forecast\n\nAccording[+283 characters]",
"sentiment": -0.2732,
"highlighted_in": "main_text"
},
{
"highlight": "For a deeper dive into these estimates, [+303 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "GuruFocus Valuation Insights\n\nGuruFocus [+212 characters]",
"sentiment": 0.1027,
"highlighted_in": "main_text"
},
{
"highlight": "For more detailed insights, visit the <e[+223 characters]",
"sentiment": 0.6705,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> (MRNA) Gains FDA Approval for New COVID-19 Vaccine",
"sentiment": 0.6705,
"highlighted_in": "title"
}
]
}
],
"similar": [
{
"uuid": "2af23be5-85bd-4549-ae73-aa1811b95b22",
"title": "Moderna wins FDA nod for next-gen COVID shot (MRNA:NASDAQ)",
"description": "Moderna (MRNA) stock in focus as the U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE,. Read more here.",
"keywords": "",
"snippet": "Moderna (NASDAQ:MRNA) announced on Saturday that the U.S. Food and Drug Administration (FDA) approved its next-gen COVID-19 vaccine, mNEXSPIKE (mRNA-1283), maki...",
"url": "https://seekingalpha.com/news/4454033-moderna-wins-fda-nod-next-gen-covid-shot",
"image_url": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1288670274/image_1288670274.jpg?io=getty-c-w750",
"language": "en",
"published_at": "2025-05-31T11:33:27.000000Z",
"source": "seekingalpha.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 45.410225,
"sentiment_score": 0.4967,
"highlights": [
{
"highlight": "<em>Moderna</em> (<em>NASDAQ:MRNA</em>) [+295 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> wins FDA nod for next-gen COVID shot (MRNA:NASDAQ)",
"sentiment": 0.5719,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "1288ee00-2918-44e8-8dac-7d1b55a66f14",
"title": "Moderna Inc (MRNA) Secures FDA Approval for mNEXSPIKE COVID-19 Vaccine | MRNA stock news",
"description": "Summary Moderna Inc (MRNA) announced on May 31, 2025, that the U.S. Food and Drug Administration (FDA) has approved its new COVID-19 vaccine, mNEXSPIKE® (mRNA-",
"keywords": "GuruFocus, Article, News, GuruFocus News, MRNA",
"snippet": "Summary\n\nModerna Inc (MRNA, Financial) announced on May 31, 2025, that the U.S. Food and Drug Administration (FDA) has approved its new COVID-19 vaccine, mNEXSP...",
"url": "https://www.gurufocus.com/news/2899894/moderna-inc-mrna-secures-fda-approval-for-mnexspike-covid19-vaccine-mrna-stock-news",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T10:01:11.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 63.439373,
"sentiment_score": 0.33,
"highlights": [
{
"highlight": "Summary\n\n<em>Moderna</em> <em>Inc</em> ([+275 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> plans to make mNEXSPIKE[+252 characters]",
"sentiment": -0.877,
"highlighted_in": "main_text"
},
{
"highlight": "Financial Analyst Perspective\n\nFrom a fi[+266 characters]",
"sentiment": 0.9153,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nIn [+273 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> expects mNEXSPIKE to be[+238 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> <em>Inc</em> (MRNA) Secures FDA Approval for mNEXSPIKE COVID-19 Vaccine | MRNA stock news",
"sentiment": 0.6597,
"highlighted_in": "title"
}
]
},
{
"symbol": "MRNA.MX",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 63.44149,
"sentiment_score": 0.33,
"highlights": [
{
"highlight": "Summary\n\n<em>Moderna</em> <em>Inc</em> ([+275 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> plans to make mNEXSPIKE[+252 characters]",
"sentiment": -0.877,
"highlighted_in": "main_text"
},
{
"highlight": "Financial Analyst Perspective\n\nFrom a fi[+266 characters]",
"sentiment": 0.9153,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nIn [+273 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> expects mNEXSPIKE to be[+238 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> <em>Inc</em> (MRNA) Secures FDA Approval for mNEXSPIKE COVID-19 Vaccine | MRNA stock news",
"sentiment": 0.6597,
"highlighted_in": "title"
}
]
},
{
"symbol": "0A45.L",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 63.44046,
"sentiment_score": 0.33,
"highlights": [
{
"highlight": "Summary\n\n<em>Moderna</em> <em>Inc</em> ([+275 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> plans to make mNEXSPIKE[+252 characters]",
"sentiment": -0.877,
"highlighted_in": "main_text"
},
{
"highlight": "Financial Analyst Perspective\n\nFrom a fi[+266 characters]",
"sentiment": 0.9153,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nIn [+273 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> expects mNEXSPIKE to be[+238 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> <em>Inc</em> (MRNA) Secures FDA Approval for mNEXSPIKE COVID-19 Vaccine | MRNA stock news",
"sentiment": 0.6597,
"highlighted_in": "title"
}
]
},
{
"symbol": "M1RN34.SA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 63.440987,
"sentiment_score": 0.33,
"highlights": [
{
"highlight": "Summary\n\n<em>Moderna</em> <em>Inc</em> ([+275 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> plans to make mNEXSPIKE[+252 characters]",
"sentiment": -0.877,
"highlighted_in": "main_text"
},
{
"highlight": "Financial Analyst Perspective\n\nFrom a fi[+266 characters]",
"sentiment": 0.9153,
"highlighted_in": "main_text"
},
{
"highlight": "Market Research Analyst Perspective\n\nIn [+273 characters]",
"sentiment": 0.5423,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> expects mNEXSPIKE to be[+238 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> <em>Inc</em> (MRNA) Secures FDA Approval for mNEXSPIKE COVID-19 Vaccine | MRNA stock news",
"sentiment": 0.6597,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "1bc3799d-4230-498a-ac8e-9f3749c3fbd7",
"title": "Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE",
"description": "mNEXSPIKE becomes Moderna's third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S",
"keywords": "GuruFocus, Article, News, ACCESSWIRE, NAS:MRNA",
"snippet": "mNEXSPIKE becomes Moderna's third FDA-approved product\n\nCAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U....",
"url": "https://www.gurufocus.com/news/2899891/moderna-receives-us-fda-approval-for-covid19-vaccine-mnexspike",
"image_url": "https://static.gurufocus.com/images/global_logo_twitter_card.png",
"language": "en",
"published_at": "2025-05-31T09:00:02.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.63357,
"sentiment_score": 0.2607,
"highlights": [
{
"highlight": "mNEXSPIKE becomes Moderna's third FDA-ap[+149 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "We appreciate the FDA's timely review an[+104 characters]",
"sentiment": 0.7506,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> expects to have mNEXSPI[+274 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Moderna</em>\n\n<em>Moderna</em>[+222 characters]",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "With a unique culture and a global team [+199 characters]",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "For more information about <em>Moderna</[+204 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "IMPORTANT SAFETY INFORMATION\n\nYou should[+248 characters]",
"sentiment": 0.0428,
"highlighted_in": "main_text"
},
{
"highlight": "These risks, uncertainties, and other fa[+251 characters]",
"sentiment": -0.8442,
"highlighted_in": "main_text"
},
{
"highlight": "Except as required by law, <em>Moderna</[+200 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> Contacts\n\nMedia:\n\nChris[+244 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE",
"sentiment": 0.4767,
"highlighted_in": "title"
}
]
},
{
"symbol": "M1RN34.SA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 34.211674,
"sentiment_score": 0.2607,
"highlights": [
{
"highlight": "mNEXSPIKE becomes Moderna's third FDA-ap[+140 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "We appreciate the FDA's timely review an[+104 characters]",
"sentiment": 0.7506,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> expects to have mNEXSPI[+274 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Moderna</em>\n\n<em>Moderna</em>[+222 characters]",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "With a unique culture and a global team [+199 characters]",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "For more information about <em>Moderna</[+204 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "IMPORTANT SAFETY INFORMATION\n\nYou should[+248 characters]",
"sentiment": 0.0428,
"highlighted_in": "main_text"
},
{
"highlight": "These risks, uncertainties, and other fa[+251 characters]",
"sentiment": -0.8442,
"highlighted_in": "main_text"
},
{
"highlight": "Except as required by law, <em>Moderna</[+200 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> Contacts\n\nMedia:\n\nChris[+244 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE",
"sentiment": 0.4767,
"highlighted_in": "title"
}
]
},
{
"symbol": "MRNA.MX",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 34.211327,
"sentiment_score": 0.2607,
"highlights": [
{
"highlight": "mNEXSPIKE becomes Moderna's third FDA-ap[+140 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "We appreciate the FDA's timely review an[+104 characters]",
"sentiment": 0.7506,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> expects to have mNEXSPI[+274 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Moderna</em>\n\n<em>Moderna</em>[+222 characters]",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "With a unique culture and a global team [+199 characters]",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "For more information about <em>Moderna</[+204 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "IMPORTANT SAFETY INFORMATION\n\nYou should[+248 characters]",
"sentiment": 0.0428,
"highlighted_in": "main_text"
},
{
"highlight": "These risks, uncertainties, and other fa[+251 characters]",
"sentiment": -0.8442,
"highlighted_in": "main_text"
},
{
"highlight": "Except as required by law, <em>Moderna</[+200 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> Contacts\n\nMedia:\n\nChris[+244 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE",
"sentiment": 0.4767,
"highlighted_in": "title"
}
]
},
{
"symbol": "0A45.L",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 34.210655,
"sentiment_score": 0.2607,
"highlights": [
{
"highlight": "mNEXSPIKE becomes Moderna's third FDA-ap[+140 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "We appreciate the FDA's timely review an[+104 characters]",
"sentiment": 0.7506,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> expects to have mNEXSPI[+274 characters]",
"sentiment": 0.4215,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>Moderna</em>\n\n<em>Moderna</em>[+222 characters]",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "With a unique culture and a global team [+199 characters]",
"sentiment": 0.7845,
"highlighted_in": "main_text"
},
{
"highlight": "For more information about <em>Moderna</[+204 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "IMPORTANT SAFETY INFORMATION\n\nYou should[+248 characters]",
"sentiment": 0.0428,
"highlighted_in": "main_text"
},
{
"highlight": "These risks, uncertainties, and other fa[+251 characters]",
"sentiment": -0.8442,
"highlighted_in": "main_text"
},
{
"highlight": "Except as required by law, <em>Moderna</[+200 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> Contacts\n\nMedia:\n\nChris[+244 characters]",
"sentiment": 0.3182,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE",
"sentiment": 0.4767,
"highlighted_in": "title"
}
]
}
]
},
{
"uuid": "b4b39ad2-2f35-44ee-a21f-86c5e500b793",
"title": "Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE | MRNA Stock News",
"description": "Moderna (MRNA) receives FDA approval for its third product, the mNEXSPIKE COVID-19 vaccine. mNEXSPIKE shows 9.3% higher efficacy compared to the origina",
"keywords": "GuruFocus, Article, News, GuruFocus News, MRNA",
"snippet": "Moderna (MRNA, Financial) receives FDA approval for its third product, the mNEXSPIKE COVID-19 vaccine.\n\nmNEXSPIKE shows 9.3% higher efficacy compared to the ori...",
"url": "https://www.gurufocus.com/news/2899872/moderna-receives-us-fda-approval-for-covid19-vaccine-mnexspike-mrna-stock-news",
"image_url": "https://static.gurufocus.com/logos/0C0000BJB3.png?20",
"language": "en",
"published_at": "2025-05-31T05:30:11.000000Z",
"source": "gurufocus.com",
"relevance_score": null,
"entities": [
{
"symbol": "MRNA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Healthcare",
"match_score": 37.058163,
"sentiment_score": 0.48685,
"highlights": [
{
"highlight": "<em>Moderna</em> (MRNA, Financial) recei[+317 characters]",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em>, <em>Inc</em>. (MRNA) h[+190 characters]",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> plans to introduce mNEX[+312 characters]",
"sentiment": -0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE | MRNA Stock News",
"sentiment": 0.4767,
"highlighted_in": "title"
}
]
},
{
"symbol": "MRNA.MX",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "mx",
"type": "equity",
"industry": "Healthcare",
"match_score": 37.058495,
"sentiment_score": 0.48685,
"highlights": [
{
"highlight": "<em>Moderna</em> (MRNA, Financial) recei[+317 characters]",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em>, <em>Inc</em>. (MRNA) h[+190 characters]",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> plans to introduce mNEX[+312 characters]",
"sentiment": -0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE | MRNA Stock News",
"sentiment": 0.4767,
"highlighted_in": "title"
}
]
},
{
"symbol": "0A45.L",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "gb",
"type": "equity",
"industry": "N/A",
"match_score": 37.05841,
"sentiment_score": 0.48685,
"highlights": [
{
"highlight": "<em>Moderna</em> (MRNA, Financial) recei[+317 characters]",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em>, <em>Inc</em>. (MRNA) h[+190 characters]",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> plans to introduce mNEX[+312 characters]",
"sentiment": -0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE | MRNA Stock News",
"sentiment": 0.4767,
"highlighted_in": "title"
}
]
},
{
"symbol": "M1RN34.SA",
"name": "Moderna, Inc.",
"exchange": null,
"exchange_long": null,
"country": "br",
"type": "equity",
"industry": "Healthcare",
"match_score": 37.058945,
"sentiment_score": 0.48685,
"highlights": [
{
"highlight": "<em>Moderna</em> (MRNA, Financial) recei[+317 characters]",
"sentiment": 0.8126,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em>, <em>Inc</em>. (MRNA) h[+190 characters]",
"sentiment": 0.836,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> plans to introduce mNEX[+312 characters]",
"sentiment": -0.1779,
"highlighted_in": "main_text"
},
{
"highlight": "<em>Moderna</em> Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE | MRNA Stock News",
"sentiment": 0.4767,
"highlighted_in": "title"
}
]
}
]
}
]
},
{
"uuid": "e5dcca8f-e30d-4e04-9677-344bb17a69f3",
"title": "UiPath price target raised to $15 from $12 at TD Cowen",
"description": "TD Cowen raised the firm’s price target on UiPath (PATH) to $15 from $12 and keeps a Hold rating on the shares. The firm said its 1Q performance exceeded expectations while 2Q and revised FY26 outlooks are above Street with revenue and EBIT reflecting healthy outperformance and ARR slightly higher, while adjusted FCF was affirmed. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing stocks on TipRanks >> Read",
"keywords": "Cowen",
"snippet": "TD Cowen raised the firm’s price target on UiPath (PATH) to $15 from $12 and keeps a Hold rating on the shares. The firm said its 1Q performance exceeded expe...",
"url": "https://finance.yahoo.com/news/uipath-price-target-raised-15-124649802.html",
"image_url": "https://media.zenfs.com/en/tipranks_452/740f5b35098ee61dacb714fa2bfeccc8",
"language": "en",
"published_at": "2025-05-31T12:46:49.000000Z",
"source": "finance.yahoo.com",
"relevance_score": null,
"entities": [
{
"symbol": "PATH",
"name": "UiPath Inc.",
"exchange": null,
"exchange_long": null,
"country": "us",
"type": "equity",
"industry": "Technology",
"match_score": 42.33195,
"sentiment_score": 0.1998,
"highlights": [
{
"highlight": "TD Cowen raised the firm’s price targe[+312 characters]",
"sentiment": 0.5994,
"highlighted_in": "main_text"
},
{
"highlight": "Try Now>>\n\nSee today’s best-performing[+91 characters]",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "<em>UiPath</em> price target raised to $15 from $12 at TD Cowen",
"sentiment": 0,
"highlighted_in": "title"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "us",
"total_documents": 1845,
"sentiment_avg": 0.2816216355101661
}
]
}
Other details
Entity count
- 32,649